<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5BNLMID%5D&amp;utm_source = Chrome&amp;utm_contm_content = 101560960＆v = 2.18.post9+epost9 +eeef9 +ee.ut = 943＆fc = none＆utm_campaign =期刊<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_source=Chrome&amp;utm_content=101560960&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20250205194943&amp;fc=None&amp;utm_campaign=journals" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> THU，2025年2月6日00:49:44 +0000</lastbuilddate><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>胰岛类器官：糖尿病中胰岛移植的新希望</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906747/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_content = 101560960&amp;fc=none&amp;fc=none&amp;ff=202202020202020202020202020202020202020202020202020202020202020202020202020202020202020202202020202020202020202020999太体群<description>由于胰岛素产生的β细胞的破坏或功能障碍，包括1型糖尿病（T1D）和晚期2型糖尿病（T2D）（T2D）的糖尿病仍然是全球健康挑战。胰岛移植提供了有希望的治疗策略。但是，它受到全球器官短缺和其他风险因素的限制。器官技术的最新进展为胰岛再生提供了变革性解决方案。这篇评论概述了三种开创性方法：胰岛... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日； 15：1540209。 doi：10.3389/fimmu.2024.1540209。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">由于胰岛素产生的β细胞的破坏或功能障碍，包括1型糖尿病（T1D）和晚期2型糖尿病（T2D）（T2D）的糖尿病仍然是全球健康挑战。胰岛移植提供了有希望的治疗策略。但是，它受到全球器官短缺和其他风险因素的限制。器官技术的最新进展为胰岛再生提供了变革性解决方案。这篇综述总结了三种开创性方法：与PROCR+胰腺祖细胞区分开的胰岛类器官，化学诱导的多能干细胞（CIPSC）和内胚层干细胞（ENSC）。 PROCR+细胞表现出多能力和<i>体内</i>激活的潜力，为β细胞再生提供了可扩展和非侵入性策略。通过小分子重新编程的CIPSC可以实现具有有希望的临床结果的个性化胰岛疗法，如T1D患者所证明的那样。 ENSC衍生的胰岛（E-ISLET）具有高分化效率和治疗功效，特别是对于残留β细胞功能的T2D患者。尽管每种方法都解决了胰岛移植中的特定挑战，但仍需要进一步的研究来优化可伸缩性，免疫兼容性和长期功能。这篇评论凸显了基于器官的技术革新糖尿病治疗的潜力，并为个性化治疗疗法铺平了道路。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906747/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906747</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790636/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790636</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1540209>10.3389/fimmu.2024.1540209</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906747</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Xuemei yu</dc:creator><dc:creator> Chengong Liu</dc:creator><dc:creator>郑孔</dc:creator><dc:creator>Siyuan歌曲</dc:creator><dc:creator>Limin Tian</dc:creator><dc:creator> Yi Wang</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>胰岛类器官：糖尿病中胰岛移植的新希望</dc:title><dc:identifier>PMID：39906747</dc:identifier><dc:identifier> PMC：PMC11790636</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1540209</dc:identifier></item><item><title>驾驶自动查询和评分系统，以促进APD的患者识别卫生系统的识别</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906746/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign =<description>结论：疾病特异性查询是一种相对简单的方法，可以在稀有疾病范围内培养患者鉴定。对于在美国提供了批准的，特定于途径的治疗的APD的疾病，这种方法甚至更为重要。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日； 15：1508780。 doi：10.3389/fimmu.2024.1508780。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：活化的PI3Kδ综合征（APD）的患者可能会在近十年内避免诊断。需要加快这些患者的鉴定以及其他具有免疫力错误（IEI）的患者的方法。我们试图证明，通过将不同的标志汇总到风险评分中可以识别这些患者来查询电子健康记录（EHR）系统。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们使用映射到<i>ICD-10-CM</i>代码的文献验证的APDS相关临床概念开发了一种结构化查询语言（SQL）脚本。我们从7个大型的，美国的医疗中心进行了大约1700万患者的EHR查询。查询计算出“ APDS分数”，该分数对这些系统中所有个体的APD进行了分层。比较了所有已知APD患者（n = 46）的评分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：该查询确定了APDS（98％; 45/46）以及其他复杂疾病的患者以外的所有患者。所有APD患者的中位数分数为9（IQR = 5.75；范围1-25）。灵敏度分析表明，最佳截止得分为7（灵敏度= 0.70）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：疾病特异性查询是一种相对简单的方法，可以在稀有疾病范围内培养患者鉴定。对于在美国提供了批准的，特定于途径的治疗的APD的疾病，这种方法甚至更为重要。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906746/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906746</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790479/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790479</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1508780>10.3389/fimmu.2024.1508780</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906746</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Amy M Fitzpatrick</dc:creator><dc:creator>亚伦·下巴</dc:creator><dc:creator>沙龙·尼伦伯格（Sharon Nirenberg）</dc:creator><dc:creator>夏洛特·坎宁安（Charlotte Cunningham）</dc:creator><dc:creator>基思·萨科</dc:creator><dc:creator>杰西·佩尔莫特（Jesse Perlmutter）</dc:creator><dc:creator>约瑟夫·达索（Joseph F Dasso）</dc:creator><dc:creator> Athanasios Tsalatsanis</dc:creator><dc:creator>杰伊·马鲁（Jay Maru）</dc:creator><dc:creator>杰西卡·克里奇（Jessica Creech）</dc:creator><dc:creator>乔兰·沃尔特（Jolan E Walter）</dc:creator><dc:creator>尼古拉斯·哈托格（Nicholas Hartog）</dc:creator><dc:creator>尼玛·伊扎迪（Neema Izadi）</dc:creator><dc:creator> Mandy Palmucci</dc:creator><dc:creator> Manish J Butte</dc:creator><dc:creator>克劳斯·洛维（Klaus Loewy）</dc:creator><dc:creator>阿努拉格·雷兰（Anurag Relan）</dc:creator><dc:creator>尼古拉斯·骑手</dc:creator><dc:date>2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>驾驶自动查询和评分系统，以促进APD的患者识别卫生系统的识别</dc:title><dc:identifier>PMID：39906746</dc:identifier><dc:identifier> PMC：PMC11790479</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1508780</dc:identifier></item><item><title>先前报道的Pemphigus药物触发器的全面，人口水平评估突出了免疫调节能力作为常见的特征</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906745/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description>结论和相关性：这项研究代表了使用现实世界数据对可疑的Pemphigus药物触发器的全面评估。这里报道的重要关联为某些药物作为PV的触发因子的假设提供了经验支持。此外，这项研究中发现与PV有关的所有药物都具有免疫调节能力，这表明直接或间接诱导这种扰动的能力可能是连接药物的关键因素... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日； 15：1508129。 doi：10.3389/fimmu.2024.1508129。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">问题：以前是否可以使用人口级别的数据来重现对假定触发药物的任何综合列表与Pemphigus的发展之间的轶事关联？ </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">调查结果：在一系列的观察，回顾性，病例控制，FDA不良事件报告系统的药物防治分析中，报告不良事件Pemphigus的几率显着升高到暴露于先前报道的11/36的个体中硫氨酸酯，青霉素，吡格糖，利福平，羟基氯喹，咪喹莫德，氢氯噻嗪，irbesartan，Lisinopril，Nivolumab和Nifedipine。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">含义：环境暴露（例如药物）是自身免疫性疾病和临床医生的发病机理中的相关参与者，这些临床医生治疗患有自身免疫性疾病的患者，例如Pemphigus对患者的纵向监测，以更好地为临床护理决定提供信息。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：Pemphigus dulgaris（PV）是一种罕见的，潜在的致命自身免疫性疾病，具有遗传和环境因素的致病性贡献，尤其是药物暴露。尽管轶事报告将多种药物与PV联系起来，但仍缺少来自大型数据集的证据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：检查以前报告的36种药物清单之间与PV发病机理有关的综合列表之间的关联的程度，可以使用人群级药物宣传数据来复制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计：一系列观察性，回顾性，病例对照，药物措施分析（一种分析/药物，总计36）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设置：基于人群。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">参与者：从2003年第四季度到2023年第2季度向FDA提交了与药物有关的不良事件报告的个人。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：通过Meddra首选术语“ Pemphigus”（10034280）描述的不良事件的存在来确定病例，然后根据暴露于每种感兴趣的药物而进行排序。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：报告量比（RORS）量化给定药物暴露与Pemphigus不良事件的报告之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：分析揭示了Pemphigus报告与暴露于先前报道的药物之间的统计学意义，其中两种含量特别高（>; 200）[硫代钠硫酸钠（ROR，266.0; 95％CI，202.6-349.3）和羟氯喹（ROR，282.6; 95％CI，261.0-306.1）]，三个具有非常强大的ror（14-45）[青霉素（ROR，30.5; 95％CI; 95％CI，11.4-81.7），Piroxicam（Ror，14.8; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95》; ％CI，8.2-26.7）和inimiquimod（Ror，42.3; 95％CI，26.2-68.3）]，六个具有适度的强度（2-5）[Rifampin（Ror，2.8; 95％CI，1.4-5.6，1.4-5.6 ），氢氯噻嗪（ROR，1.6; 95％CI，1.2-2.1），Irbesartan（Ror，2.7; 95％CI，1.6-4.4），Lisinopril（Ror，5.3; 95％CI，4.5-6.2），ror（nivolumab（Nivolumab（Nivolumab）） ，2.7; 95％CI，1.8-4.1）和Nifedipine（ROR，3.0; 95％CI，1.9-5.0）。未检测到其他先前报道的药物的关联（25/36）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：这项研究代表了使用现实世界数据对可疑的Pemphigus药物触发器的全面评估。这里报道的重要关联为某些药物作为PV的触发因子的假设提供了经验支持。此外，这项研究中发现与PV有关的所有药物具有免疫调节能力，这表明直接或间接诱导这种扰动的能力可能是将暴露于Pemphigus发病机理的药物接触的关键因素。但是，其他先前报道的假定触发药物没有信号并不能排除其在PV发病机理中的潜在作用。我们的发现加强了对更大，更确定的研究的需求，以确认这些关联并探索这些药物可能有助于PV开发的机制。最后，这些发现强调了在遗传易感人群中考虑环境因素在PV发展和过程中的重要性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906745/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906745</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790476/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790476</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1508129>10.3389/fimmu.2024.1508129</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906745</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>贾斯汀·巴鲁基安（Justin Baroukhian）</dc:creator><dc:creator> Kristina Seiffert-Sinha</dc:creator><dc:creator> Animesh sinha</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>先前报道的Pemphigus药物触发器的全面，人口水平评估突出了免疫调节能力作为常见的特征</dc:title><dc:identifier>PMID：39906745</dc:identifier><dc:identifier> PMC：PMC11790476</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1508129</dc:identifier></item><item><title> BTK抑制剂Zanubrutinib的随机，安慰剂对照试验在住院的Covid-19呼吸窘迫中：免疫生物标志物和临床发现</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description>结论：在接受Zanubrutinib的Covid-19呼吸窘迫患者中观察到炎症信号传导显着降低，SARS-COV-2血清学反应的降低明显减少。尽管有这些免疫学发现，但扎努布替尼在从呼吸窘迫中恢复临床恢复中并未显示出对安慰剂的改善。对大多数患者的类固醇和抗病毒疗法的同时服用可能会导致这些结果。可能需要对Zanubrutinib进行调查... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日； 15：1369619。 doi：10.3389/fimmu.2024.1369619。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：通过多动免疫反应触发的细胞因子释放被认为导致严重的急性呼吸综合征冠状病毒2019（SARS-COV-2）相关的呼吸衰竭。布鲁顿酪氨酸激酶（BTK）参与先天免疫，而BTK抑制剂阻止细胞因子释放。我们评估了下一代BTK抑制剂Zanubrutinib在患有呼吸窘迫的SARS-COV-2感染患者中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：1具有前瞻性，随机，双盲，安慰剂对照的设计；队列2具有单臂设计。在队列1中随机分配了需要住院的SARS-COV-2的成年人。 ），或每天接受Zanubrutinib 320 mg（队列2）。共同主要的终点是无呼吸衰竭的生存率和时间在28天后返回呼吸空气的时间。进行了评估Zanubrutinib对免疫反应的影响的推论研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：16例同类中的63例患者接受Zanubrutinib（n = 30）或安慰剂（n = 33），中位治疗时间分别为8.5和7.0天。队列2（n = 4）的中位治疗持续时间为13天；所有人都早点停止治疗。在队列1中，无呼吸衰竭的生存期和在第28天之前未返回呼吸空气的估计率在两次治疗之间没有显着差异。重要的是，Zanubrutinib对2019年冠状病毒疾病的血清学反应没有影响。在Zanubrutinib治疗的患者中观察到较低水平的粒细胞刺激因子，白介素（IL）-10，单核细胞化学吸引蛋白-1，IL-4和IL-13。此外，单细胞转录组分析显示，炎症介质（IL-6，IL-8，巨噬细胞刺激因子，巨噬细胞炎性蛋白1α，IL-1β）和信号通路（JAK1，STAT3，TYK2）和Zanubruutinib治疗的患者γ--二硫代T细胞的激活。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在接受Zanubrutinib的Covid-19呼吸窘迫患者中观察到炎症信号传导显着降低，SARS-COV-2血清学反应的降低明显减少。尽管有这些免疫学发现，但扎努布替尼在从呼吸窘迫中恢复临床恢复中并未显示出对安慰剂的改善。对大多数患者的类固醇和抗病毒疗法的同时服用可能会导致这些结果。在细胞因子释放和免疫细胞衰竭很重要的其他情况下，可能需要对ZANUBRUTIN进行研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验注册：https：//www.clinicaltrials.gov/study/NCT04382586，标识符NCT04382586。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906744/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906744</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11791645/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11791645</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1369619>10.3389/fimmu.2024.1369619</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906744</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>史蒂文·P·特里昂（Steven P Treon）</dc:creator><dc:creator> Camille N Kotton</dc:creator><dc:creator>大卫J公园</dc:creator><dc:creator>Giorgia Moranzoni</dc:creator><dc:creator> Camilla K Lemvigh</dc:creator><dc:creator>约瑟夫·C盖斯</dc:creator><dc:creator>Tilly a varughese</dc:creator><dc:creator>克里斯托弗·巴内特（Christopher F Barnett）</dc:creator><dc:creator>约翰尼·M·贝伦奇（Johnny M Belenchia）</dc:creator><dc:creator>妮娜·克拉克（Nina M Clark）</dc:creator><dc:creator>查尔斯·M·法伯（Charles M Farber）</dc:creator><dc:creator>穆罕默德·比拉尔·阿比德（Muhammad Bilal Abid）</dc:creator><dc:creator>古雷兹·艾哈迈德（Gulrayz Ahmed）</dc:creator><dc:creator>克里斯托弗·J·帕特森（Christopher J Patterson）</dc:creator><dc:creator>玛丽亚·格雷拉（Maria L Guerrera）</dc:creator><dc:creator>雅各布·索梅拉伊</dc:creator><dc:creator>vipheaviny a chea</dc:creator><dc:creator>伊莎贝尔P Carulli</dc:creator><dc:creator>杰克逊·索萨德（Jackson Southard）</dc:creator><dc:creator> Shuqiang li</dc:creator><dc:creator>凯瑟琳·J·吴（Catherine J Wu）</dc:creator><dc:creator>肯尼斯·J·利瓦克（Kenneth J Livak）</dc:creator><dc:creator>埃里克·霍姆格伦（Eric Holmgren）</dc:creator><dc:creator>比尔金</dc:creator><dc:creator>嘉莉·什（Carrie Shi）</dc:creator><dc:creator> Holly Lin</dc:creator><dc:creator> Vanitha Ramakrishnan</dc:creator><dc:creator> ying ou</dc:creator><dc:creator> Scott Olszewski</dc:creator><dc:creator>拉尔斯·罗恩·奥尔森</dc:creator><dc:creator>Derin B Keskin</dc:creator><dc:creator> Zachary R Hunter</dc:creator><dc:creator>克里斯托弗·坦克斯利（Christopher Tankersley）</dc:creator><dc:creator>托德·齐默尔曼（Todd Zimmerman）</dc:creator><dc:creator> Binod Dhakal</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>BTK抑制剂Zanubrutinib的随机，安慰剂对照试验在住院的Covid-19呼吸窘迫中：免疫生物标志物和临床发现</dc:title><dc:identifier>PMID：39906744</dc:identifier><dc:identifier> PMC：PMC11791645</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1369619</dc:identifier></item><item><title>新型的Pyroptosis-免疫相关LNCRNA签名在乳腺癌中表现出独特的免疫细胞浸润景观</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906743/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_content = 101560960&amp;fc=none&amp;fc=none&amp;ff=202202020202020202020202020202020220202020202020220202022020202202020202202022020202020220202022020202202020202020220202022020299999Y指数<description>结论：六-lncrna Pyroptosis-免疫特征有效地预测了BC预后，并突出了不同的免疫细胞浸润模式。这有望评估免疫疗法反应并指导卑诗省的治疗靶标识别。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日； 15：1522327。 doi：10.3389/fimmu.2024.1522327。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：这项研究调查了与免疫相关的长期非编码RNA（LNCRNA），以鉴定有希望的乳腺癌治疗靶标（BC），并构建了LNCRNA特征，以确定BC患者的预后和免疫疗法反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：Pearson的相关系数用于鉴定分别与免疫相关的差异和免疫相关的LNCRNA（分别为de-pyrolncrnas和de-immlncrnas）。癌症基因组图集数据集分配给培训和测试子集。使用单变量COX回归分析以及最少的绝对收缩和选择算子方法，根据训练子集得出了预后的LNCRNA特征。逐步使用Cox回归来完善这些特征并选择最佳的lncRNA特征。将训练子集的中位风险评分作为阈值，以将患者分为高风险（HR）和低风险（LR）组。 Wilcoxon检验用于揭示这些组之间免疫评分，细胞类型，功能和检查点基因的差异。来自GSE176078的单细胞测序数据用于验证已鉴定的LNCRNA特征的免疫细胞浸润景观。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们确定了一个包括MAPT.AS1，CTA.384，D8.34，RP11.561，I11.3，HID1.AS1，AC097713.3和USP2.AS1的六lncRNA pyroptosis-免疫特征。人力资源组的患者在训练，测试和完整数据集中表现出较低的预后（p = 3.622e-07，p = 3.736E-03和p = 1.151E-08）。 LR组的免疫评分显着提高，而HR组的肿瘤纯度升高。 58个免疫评分在两组之间显示出显着差异（p &lt;0.05）。免疫功能（APC共抑制，CCR和检查点）在HR组中更加严重受损。 LR组的38个免疫检查点基因的表达水平，包括KIR2DS4，KIR3DL2，CD40LG，KIR3DL1和PDCD1的表达水平明显更高。相反，HR组的TDO2，PVR和CD276水平升高。来自GSE176078的单细胞测序数据显示HR组中的T细胞，B细胞，髓样和纤溶酶簇稀疏，而LR组显示出B细胞，髓样和纤溶酶的明显聚类。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：六-lncrna Pyroptosis-免疫特征有效地预测了BC预后，并突出了不同的免疫细胞浸润模式。这有望评估免疫疗法反应并指导卑诗省的治疗靶标识别。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906743/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906743</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790642/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790642</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1522327>10.3389/fimmu.2024.1522327</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906743</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Dedi Kong</dc:creator><dc:creator>洪朱</dc:creator><dc:creator>Meihong Wang</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>新型的Pyroptosis-免疫相关LNCRNA签名在乳腺癌中表现出独特的免疫细胞浸润景观</dc:title><dc:identifier>PMID：39906743</dc:identifier><dc:identifier> PMC：PMC11790642</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1522327</dc:identifier></item><item><title>实体瘤中组蛋白乙酰化酶的转录表达的泛伴随分析定义了新的胶质瘤分类方案</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906742/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_content = 101560960&amp;fc=none&amp;fc=none&amp;ff=2022020202020202020202020202202020220202022020220202202022020202020202020202020202022020220202202022020220202202022020202202022020220999太体<description>结论：在这里，我们基于帽子和HDAC的转录表达谱，在生物学和临床相关的分子分子上建立了新颖的分子分类。此外，由29个基因的转录表达计算得出的ACG评分模型不仅是神经胶质瘤患者的独立预后因素，而且还可以提供有价值的参考，以促进更有效的治疗策略。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日; 15：1523034。 doi：10.3389/fimmu.2024.1523034。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：编码组蛋白乙酰基转移酶（HATS）和组蛋白脱乙酰基酶（HDAC）的基因的表达改变与各种实体瘤的肿瘤发生和进展有关。然而，仍然缺乏帽子和HDAC的转录组景观和临床相关性的系统表征。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从癌症基因组地图集的31种肿瘤类型中的9,483例患者的转录组和临床数据收集以进行系统的泛伴侣分析。还收集了其他特异性数据集（中国神经胶质瘤基因组地图集，Gliovis，GSE43378和GSE182109），以验证神经胶质瘤中帽子和HDAC的转录特性。使用共识聚类分析来识别帽子和HDAC的不同表达模式。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：基于编码9个帽子和16个HDAC的25个基因的转录组数据，我们确定了31种癌症类型（AC-I至AC-V）的5种主要亚型。值得注意的是，与患有其他实体瘤的患者相比，AC-V亚型超过95％的患者占95％的患者，表明胶质瘤患者表现出不同的组蛋白乙酰化改良酶的表达模式。因此，我们在神经胶质瘤的背景下特别重新传达了共识聚类分析，并确定了五个亚型，并表示为“ AC-GI”为“ AC-GV”，其特征是帽子/HDACS表达模式的差异，生物学和免疫状态，遗传改变和临床结果。 AC-GII患者表现出最好的预后，对替莫唑胺敏感，而AC-GV患者的预后最差，对替莫唑胺的敏感性最低。此外，基于连接图数据库分析和实验验证，我们确定了几种PAN-HDAC抑制剂，这些抑制剂可以作为AC-GV患者（例如Panobinostat和Scriptaid）的替莫唑胺治疗的敏化剂。考虑到AC-GII和AC-GV患者的独特临床特征，我们构建了能够有效识别这些亚型患者并预测患者预后的“ ACG评分”模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在这里，我们基于帽子和HDAC的转录表达谱，在生物学和临床相关的分子分子上建立了新颖的分子分类。此外，由29个基因的转录表达计算得出的ACG评分模型不仅是神经胶质瘤患者的独立预后因素，而且还可以提供有价值的参考，以促进更有效的治疗策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906742/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906742</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790639/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790639</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1523034>10.3389/fimmu.2024.1523034</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906742</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>朱霍张</dc:creator><dc:creator>Lingbo Li</dc:creator><dc:creator>艾维·唐</dc:creator><dc:creator>Chucheng Wang</dc:creator><dc:creator> Yupeng Wang</dc:creator><dc:creator> Yongqi Hu</dc:creator><dc:creator>巨人他</dc:creator><dc:creator>Wangjun Liao</dc:creator><dc:creator> Rui Zhou</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>实体瘤中组蛋白乙酰化酶的转录表达的泛伴随分析定义了新的胶质瘤分类方案</dc:title><dc:identifier>PMID：39906742</dc:identifier><dc:identifier> PMC：PMC11790639</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1523034</dc:identifier></item><item><title>白介素17在炎症相关癌症中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description>新兴的证据表明炎症与癌症的发展和进展之间存在相关性。在各种炎症信号中，白介素17（IL-17）家族细胞因子是炎症与癌症之间的关键联系。 IL-17是一种高度用途的促炎细胞因子，在宿主防御，组织修复，炎症性疾病的发病机理和癌症进展中起关键作用。在肿瘤发生的早期阶段，IL-17信号直接... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日； 15：1479505。 doi：10.3389/fimmu.2024.1479505。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">新兴的证据表明炎症与癌症的发展和进展之间存在相关性。在各种炎症信号中，白介素17（IL-17）家族细胞因子是炎症与癌症之间的关键联系。 IL-17是一种高度用途的促炎细胞因子，在宿主防御，组织修复，炎症性疾病的发病机理和癌症进展中起关键作用。在肿瘤发生的早期阶段，IL-17信号直接促进肿瘤细胞的增殖。相反，已显示IL-17在几种接枝的皮下肿瘤模型中表现出抗肿瘤免疫力。另外，微生物组的动态变化会影响IL-17的分泌，从而影响肿瘤的发展。 IL-17的具体作用取决于其功能分类，时空特征和肿瘤发育阶段。在这篇综述中，我们介绍了IL-17的基本生物学及其在癌症中的受体的表达谱，同时还回顾和讨论有关与炎症相关的癌症中IL-17的多效效应和机制的最新进步。此外，我们将讨论补充了对IL-17通过与微生物群相互作用影响癌症进展的机制的见解，我们探讨了IL-17在癌症治疗中的影响。这种全面的分析旨在增强我们对IL-17及其在癌症治疗中的潜在作用的理解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906741/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906741</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790576/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790576</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1479505>10.3389/fimmu.2024.1479505</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906741</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Xingru Zhang</dc:creator><dc:creator> Bangjie Li</dc:creator><dc:creator>天兰</dc:creator><dc:creator>Conner Chiari</dc:creator><dc:creator> xiaoyang ye</dc:creator><dc:creator> Kepeng Wang</dc:creator><dc:creator> Ju Chen</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>白介素17在炎症相关癌症中的作用</dc:title><dc:identifier>PMID：39906741</dc:identifier><dc:identifier> PMC：PMC11790576</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1479505</dc:identifier></item><item><title>自动激活和保护模块增强了同种异体抗CD70 CAR-T细胞的临床前性能</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906740/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals＆utm_content = 101560960&amp;fc=none&amp;fc=none&amp;ff=2022020202020202020202020202020202020202020202020202020202020202020202020202020202020202022020202020202202022020202999太体<description>简介：同种异体嵌合抗原受体T（CAR-T）疗法，也称为Universal Car-T（UCAR-T）疗法，可提供广泛的适用性，高生产效率和降低的成本，从而使患者更快地使用。但是，临床应用仍受到免疫排斥和效力和耐用性问题等挑战的限制。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1531294。 doi：10.3389/fimmu.2024.1531294。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：同种异体嵌合抗原受体T（CAR-T）疗法，也称为Universal Car-T（UCAR-T）疗法，可提供广泛的适用性，高生产效率和降低的成本，从而使患者更快地使用。但是，临床应用仍受到免疫排斥和效力和耐用性问题等挑战的限制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们首先筛选了一个安全有效的抗CD70 SCFV，以构建抗CD70 CAR-T细胞。然后通过敲除TRAC，B2M和HLA-DRA来产生抗CD70 UCAR-T细胞。为了解决UCAR-T疗法的局限性，我们开发了一个“一对一”自动化和保护性（SAP）模块，该模块集成到CAR支架中。 SAP模块由CD47细胞外结构域，突变的白介素7受体α（IL7Rα）跨膜结构域组成，IL7Rα细胞内结构域旨在保护UCAR-T细胞，旨在保护UCAR-T细胞免受宿主免疫攻击并增强其存活。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：SAP UCAR-T细胞显示出对先天免疫系统的免疫排斥显着降低，这是<i>体外</i>和<i>体内</i>增强的生存和功能的证明。修饰的UCAR-T细胞表现出改善的持久性，没有观察到的安全问题。此外，SAP UCAR-T细胞在扩大生产过程中保持了过程稳定性，这表明可能进行大规模制造。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：我们的发现突出了SAP模块是抗CD70 UCAR-T的临床前开发的有希望的策略，为“现成”细胞疗法产品铺平了道路。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906740/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906740</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11792090/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11792090</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1531294>10.3389/fimmu.2024.1531294</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906740</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>张张</dc:creator><dc:creator>Lianfeng Zhao</dc:creator><dc:creator> Tinghui Huang</dc:creator><dc:creator> Zhengliang Chen</dc:creator><dc:creator> Yaoyao Zhao</dc:creator><dc:creator> JunQing Liang</dc:creator><dc:creator> Xudong Ao</dc:creator><dc:creator> xiaoqiong jia</dc:creator><dc:creator> Lei Kang</dc:creator><dc:creator> Linghui Kong</dc:creator><dc:creator>齐王</dc:creator><dc:creator>Jianhua Hu</dc:creator><dc:creator>莉莉·古（Lili Gu）</dc:creator><dc:creator> Feiyan Pan</dc:creator><dc:creator> Zhigang Hu</dc:creator><dc:creator> Lingfeng他</dc:creator><dc:creator>Muya Zhou</dc:creator><dc:creator>江恩·陈</dc:creator><dc:creator>Zhigang Guo</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>自动激活和保护模块增强了同种异体抗CD70 CAR-T细胞的临床前性能</dc:title><dc:identifier>PMID：39906740</dc:identifier><dc:identifier> PMC：PMC11792090</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1531294</dc:identifier></item><item><title> &lt;em>; erap1 &lt;/em>;和&lt;em>; erap2 &lt;/em>;基因多态性和ERAP2蛋白的关联与乌克兰人口中类风湿关节炎的敏感性和严重程度的关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description>结论：某些ERAP1和ERAP2多态性似乎与对RA的易感性或疾病的严重程度有关。在血清中测试的ERAP2蛋白可能是RA严重程度的有价值的生物标志物。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月21日； 15：1519159。 doi：10.3389/fimmu.2024.1519159。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：类风湿关节炎（RA）是一种长期自身免疫性疾病，主要影响关节。尽管RA主要与II类HLA相关，但是也观察到了一些HLA I类协会。这些分子对CD8+ T淋巴细胞和天然杀伤细胞呈现抗原肽。 HLA-1分子在内质网中结合其肽货物（长8-10氨基酸）。超过10个氨基酸的肽被内质网氨基肽酶ERAP1和ERAP2修剪，以适合HLA-I分子的肽结合凹槽。在这里，我们研究了<i>ERAP1</i>和<i>ERAP2</i>多态性与RA的可能关联，以及ERAP2蛋白血清水平与疾病严重程度之间的任何可能相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们将实时PCR用于基因型<i>ERAP1</i>和<i>ERAP2</i>和ELISA检测来检测<i>ERAP2</i>蛋白。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现<i>ERAP1</i> RS30187，RS27044和RS26618以及<i>ERAP2</i> RS2248374的显着关联与对RA的敏感性。 <i>ERAP1</i> RS26653和ERAP2 RS2248374也与疾病活性评分（DAS28）有关，并且某些多态性也与抗抗抗抗素化的蛋白或抗突出的柠檬酸柠檬酸奶油蛋白抗体有关。 RA患者分泌的ERAP2高于对照。轻度疾病活性的患者（DAS28 &lt;3.2）的ERAP2浓度比严重疾病活性的患者低四倍（DAS28>; 5.1）。与RF阴性患者相比，我们检测到类风湿因子（RF）阳性患者的<i>ERAP2</i>水平更高。 <i>ERAP2</i>浓度高于5.85 ng/mL，表明RA的严重相。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：某些<i>ERAP1</i>和<i>ERAP2</i>多态性似乎与对RA的易感性或疾病的严重程度有关。在血清中测试的ERAP2蛋白可能是RA严重程度的有价值的生物标志物。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39906739/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906739</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790443/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790443</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1519159>10.3389/fimmu.2024.1519159</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39906739</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Iryna Kril</dc:creator><dc:creator> Andrzejwiśniewski</dc:creator><dc:creator> Agnieszka Tarnowska</dc:creator><dc:creator> Khrystyna Lishchuk-Yakymovych</dc:creator><dc:creator> Yaryna Bojko</dc:creator><dc:creator> piotrkuśnierczyk</dc:creator><dc:creator> Valentyna v dopyak</dc:creator><dc:creator> Izabela Nowak</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>免疫学领域</dc:source><dc:title>Association of &lt;em>;ERAP1&lt;/em>; and &lt;em>;ERAP2&lt;/em>; gene polymorphisms and ERAP2 protein with the susceptibility and severity of rheumatoid arthritis in the Ukrainian population</dc:title><dc:identifier> pmid:39906739</dc:identifier><dc:identifier> pmc:PMC11790443</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1519159</dc:identifier></item><item><title> Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy</title><link/> https://pubmed.ncbi.nlm.nih.gov/39906738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description> CONCLUSION: IBI is the best inflammatory index to predict the prognosis of advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy, which will help guide patients&#39; treatment decisions. This result still needs to be verified by large prospective studies. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 21;15:1471399. doi: 10.3389/fimmu.2024.1471399. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Blood inflammation index has been shown to correlate with the prognosis of patients with gastric cancer. However, few studies have compared the efficacy of existing blood inflammatory markers in predicting the prognosis of patients with locally advanced gastric cancer in combination with neoadjuvant chemotherapy and immunotherapy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: The objective of this study was to compare the prognostic value of existing commonly used blood inflammatory index in patients with advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The clinicopathological data of patients with advanced gastric cancer from three centers in China were analyzed retrospectively. Univariate COX regression analysis was used to analyze the independent risk factors of poor tumor regression and overall survival (OS) in this part of patients, and the predictive value of different inflammatory indexes on prognosis was compared by C-index index. Finally, Inflammatory burden index(IBI) was grouped by X-tile software, and Kaplan-Meier method was used to compare the survival difference between groups. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 163 patients were enrolled in this study. The median age was 63 years(56-68). The median cycle of neoadjuvant therapy was 4(3-4). The median survival time was 85.1%(1 years), 65.6%(2 years), and 47.4%(3 years).Univariate analysis showed that IBI was an independent risk factor for non-TR(residual tumor cells>;50%) (HR=1.08,95%CI:1.00-1.45,p&lt;0.001)and OS(HR=1.04,95%CI:1.03-1.05,p&lt;0.001). IBI is the best predictor of OS (C-index: 0.82, 95% CI: 0.78-0.87) among all inflammatory indexes. The IBI cutoff value was 52.1. It was found that the high IBI group had a higher incidence of postoperative complications(32.1%vs14.3%, p=0.001), the proportion of non-TR patients was significantly higher than that of the low IBI group(64.3%vs35.7%, p =0.001), and the high IBI group had a significantly lower OS((47.6% vs 87.6%, p &lt; 0.001). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: IBI is the best inflammatory index to predict the prognosis of advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy, which will help guide patients&#39; treatment decisions. This result still needs to be verified by large prospective studies.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39906738/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906738</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790653/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790653</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1471399>10.3389/fimmu.2024.1471399</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39906738</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jiao-Bao Huang</dc:creator><dc:creator> Zhi-Yong Zhou</dc:creator><dc:creator> Jun Lu</dc:creator><dc:creator> Ji-Yun Zhu</dc:creator><dc:creator> Bin Lai</dc:creator><dc:creator> Sheng-Xun Mao</dc:creator><dc:creator> Jia-Qing Cao</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy</dc:title><dc:identifier> pmid:39906738</dc:identifier><dc:identifier> pmc:PMC11790653</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1471399</dc:identifier></item><item><title> Investigating the potential immunomodulatory effects of commercial oral probiotic supplements on equine gastrointestinal tract barrier function</title><link/> https://pubmed.ncbi.nlm.nih.gov/39906737/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description> CONCLUSION: The present study revealed no effect of the use of a commercial probiotic dietary supplement on either mucosal immunity or the composition of the intestinal microbiota. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 21;15:1487664. doi: 10.3389/fimmu.2024.1487664. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Oral probiotic dietary supplements are widely used in veterinary medicine, including in horses. It is hypothesized that the presence of probiotic strains can both modulate the intestinal microbiota and affect mucosal immunity parameters. Such a study has not yet been conducted in horses. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This study involved 12 healthy horses, which were randomly divided into a control group and a group that received a commercial oral probiotic formula containing <i>Lactobacillus rhamnosus</i> , <i>Pedioccus acidilactici</i> or <i>Enterococcus faecium</i> for 84 days. Fecal samples were collected from all horses on day 0 (D0), 28 days after starting the probiotic (D28), 56 days (D56), 84 days (D84) and 28 days after stopping the probiotic (DX) treatment. The samples were subjected to microbiome analysis via next-generation sequencing of hypervariable regions V3-V4 and V7-V9 of the <i>16S rRNA</i> gene for analysis of short-chain fatty acids via HPLC analysis and fecal secretory immunoglobulin A (SIgA) quantification via ELISA. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Microbiome analysis revealed no significant differences in either alpha or beta diversity parameters between the groups. No probiotic strains were detected in the samples. Significant changes were detected in three taxa: the family <i>Bacteroidales</i> RF16 group, the genus <i>Erysipelotrichaceae</i> UCG-004, and the genus <i>Fibrobacter</i> during the study in both groups. In all the cases, there was a gradual decrease in relative abundance over time. The concentrations of SCFAs, specifically acetic and propionic acids, significantly increased over time in both groups according to the generalized linear mixed effects (GLME) model. There were no significant differences in fecal SIgA secretion. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: The present study revealed no effect of the use of a commercial probiotic dietary supplement on either mucosal immunity or the composition of the intestinal microbiota.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39906737/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906737</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790434/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790434</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1487664>10.3389/fimmu.2024.1487664</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39906737</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Agnieszka Żak-Bochenek</dc:creator><dc:creator> Paulina Żebrowska-Różańska</dc:creator><dc:creator> Joanna Bajzert</dc:creator><dc:creator> Łukasz Łaczmański</dc:creator><dc:creator> Bogumiła Szponar</dc:creator><dc:creator> Natalia Siwińska</dc:creator><dc:creator> Klaudia Gładysz</dc:creator><dc:creator> Katarzyna Sikorska</dc:creator><dc:creator> Anna Chełmońska-Soyta</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Investigating the potential immunomodulatory effects of commercial oral probiotic supplements on equine gastrointestinal tract barrier function</dc:title><dc:identifier> pmid:39906737</dc:identifier><dc:identifier> pmc:PMC11790434</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1487664</dc:identifier></item><item><title> Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections</title><link/> https://pubmed.ncbi.nlm.nih.gov/39906736/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description> CONCLUSION: Adults with IEIs mounted both HI and CMI responses following COVID-19 vaccines, which were lower than those of healthy individuals but were present at least up to 6 months after dose 3. These data support the initial recommendation for a three-dose primary series among IEIs. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 21;15:1501908. doi: 10.3389/fimmu.2024.1501908. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> PURPOSE: Many individuals with inborn errors of immunity (IEIs) have poor humoral immune (HI) vaccine responses. Only a few studies have examined specific cell-mediated immune (CMI) responses to coronavirus disease 2019 (COVID-19) vaccines in this population. Therefore, the purpose of this study was to examine HI and CMI responses up to 6 months post-COVID-19 vaccine dose 3 in adults with IEIs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A multi-center prospective observational study was conducted across Canada to collect severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific HI and CMI data at 4- and 24-week intervals after vaccine doses 2 and 3 (D2 + 4wk/D2 + 24wk/D3 + 4wk/D3 + 24wk). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 149 adults with IEIs and 423 healthy controls were recruited from July 2021 to October 2023. Geometric mean anti-spike IgG (binding antibody units/mL) and spike-specific T-cell responses [IFN-γ <sup>+</sup> T cells/10 <sup>6</sup> peripheral blood mononuclear cells (PBMCs)] were significantly lower in IEIs compared to controls at D2 + 4wk, D3 + 4wk, and D3 + 24wk. However, at 6 months after completing the primary series (three doses for IEIs and two doses for healthy), both HI and CMI responses of both IEI participants and healthy controls persisted and were comparable. There was a strong correlation between neutralizing antibody titer (ID50) and anti-spike IgG but not between ID50 and CMI. There was only one reported case of hospitalized COVID-19 disease before and none after completing the primary series among IEI participants. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Adults with IEIs mounted both HI and CMI responses following COVID-19 vaccines, which were lower than those of healthy individuals but were present at least up to 6 months after dose 3. These data support the initial recommendation for a three-dose primary series among IEIs.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39906736/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906736</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790575/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790575</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1501908>10.3389/fimmu.2024.1501908</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39906736</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Dana Unninayar</dc:creator><dc:creator> Emilia L Falcone</dc:creator><dc:creator> Hugo Chapdelaine</dc:creator><dc:creator> Donald C Vinh</dc:creator><dc:creator> Karina A Top</dc:creator><dc:creator> Beata Derfalvi</dc:creator><dc:creator> Thomas B Issekutz</dc:creator><dc:creator> Hélène Decaluwe</dc:creator><dc:creator> Anne Pham-Huy</dc:creator><dc:creator> Julia Upton</dc:creator><dc:creator> Stephen D Betschel</dc:creator><dc:creator> Tamar Rubin</dc:creator><dc:creator> Sneha Suresh</dc:creator><dc:creator> Nicola AM Wright</dc:creator><dc:creator> Luis Murguía-Favela</dc:creator><dc:creator> Tatiana Kalashnikova</dc:creator><dc:creator> Lisa Barrett</dc:creator><dc:creator> Sharon Oldford</dc:creator><dc:creator> Marc-Andre Langlois</dc:creator><dc:creator> Corey Arnold</dc:creator><dc:creator> Manish Sadarangani</dc:creator><dc:creator> Tinghua Zhang</dc:creator><dc:creator> Tim Ramsay</dc:creator><dc:creator> Dina Yazji</dc:creator><dc:creator> Juthaporn Cowan</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections</dc:title><dc:identifier> pmid:39906736</dc:identifier><dc:identifier> pmc:PMC11790575</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1501908</dc:identifier></item><item><title> Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?</title><link/> https://pubmed.ncbi.nlm.nih.gov/39906735/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description> The prevalence of metabolic diseases, such as obesity, has been steadily increasing in recent years, posing a significant threat to public health. Therefore, early identification and intervention play a crucial role. With the deepening understanding of the etiology of metabolic diseases, novel therapeutic targets are emerging for the treatment of obesity, lipid metabolism disorders, cardiovascular and cerebrovascular diseases, glucose metabolism disorders, and other related metabolic conditions.... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 21;15:1498288. doi: 10.3389/fimmu.2024.1498288. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The prevalence of metabolic diseases, such as obesity, has been steadily increasing in recent years, posing a significant threat to public health. Therefore, early identification and intervention play a crucial role. With the deepening understanding of the etiology of metabolic diseases, novel therapeutic targets are emerging for the treatment of obesity, lipid metabolism disorders, cardiovascular and cerebrovascular diseases, glucose metabolism disorders, and other related metabolic conditions. IL-27, as a multi-potent cytokine, holds great promise as a potential candidate target in this regard. This article provides a comprehensive review of the latest findings on IL-27 expression and signal transduction in the regulation of immune inflammatory cells, as well as its implications in obesity and other related metabolic diseases. Furthermore, it explores the potential of IL-27 as a novel therapeutic target for the treatment of obesity and metabolic disorders. Finally, an overview is presented on both the opportunities and challenges associated with targeting IL-27 for therapeutic interventions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39906735/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906735</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11792170/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11792170</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1498288>10.3389/fimmu.2024.1498288</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39906735</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jinyang An</dc:creator><dc:creator> Donghua Fu</dc:creator><dc:creator> Ximei Chen</dc:creator><dc:creator> Conghui Guan</dc:creator><dc:creator> Lingling Li</dc:creator><dc:creator> Jia Bai</dc:creator><dc:creator> Haihong Lv</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?</dc:title><dc:identifier> pmid:39906735</dc:identifier><dc:identifier> pmc:PMC11792170</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1498288</dc:identifier></item><item><title> Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases</title><link/> https://pubmed.ncbi.nlm.nih.gov/39906123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description> Adropin is a secreted peptide encoded by the energy homeostasis-associated gene (ENHO), located chromosome 9p13.3, with a conserved amino acid sequence across humans and mice. Its expression is regulated by various factors, including fat, LXRα, ERα, ROR, and STAT3. Adropin plays a critical role in glucose and lipid metabolism, as well as insulin resistance, by modulating multiple signaling pathways that contribute to the reduction of obesity and the improvement of blood lipid and glucose... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 21;16:1482308. doi: 10.3389/fimmu.2025.1482308. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Adropin is a secreted peptide encoded by the energy homeostasis-associated gene (ENHO), located chromosome 9p13.3, with a conserved amino acid sequence across humans and mice. Its expression is regulated by various factors, including fat, LXRα, ERα, ROR, and STAT3. Adropin plays a critical role in glucose and lipid metabolism, as well as insulin resistance, by modulating multiple signaling pathways that contribute to the reduction of obesity and the improvement of blood lipid and glucose homeostasis. Additionally, it influences immune cells and inflammation, exerting anti-inflammatory effects across various diseases. While extensive research has summarized the regulation of cellular energy metabolism by adropin, limited studies have explored its role in immune regulation and inflammation. To enhance the understanding of adropin&#39;s immune-modulating and anti-inflammatory mechanisms, this review synthesizes recent findings on its effects in conditions such as atherosclerosis, diabetes, fatty liver, non-alcoholic hepatitis, and inflammation. Furthermore, the review discusses the current research limitations and outlines potential future directions for adropin-related investigations. It is hoped that ongoing research into adropin will contribute significantly to the advancement of medical treatments for various diseases.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39906123/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39906123</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11790448/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11790448</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1482308>10.3389/fimmu.2025.1482308</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39906123</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Junmin Wang</dc:creator><dc:creator> Ning Ding</dc:creator><dc:creator> Chong Chen</dc:creator><dc:creator> Simin Gu</dc:creator><dc:creator> Jing Liu</dc:creator><dc:creator> Yanping Wang</dc:creator><dc:creator> Liubing Lin</dc:creator><dc:creator> Yiyuan Zheng</dc:creator><dc:creator> Yong Li</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases</dc:title><dc:identifier> pmid:39906123</dc:identifier><dc:identifier> pmc:PMC11790448</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1482308</dc:identifier></item><item><title>使用聚类分析鉴定微观多管炎患者的新型临床亚型：多中心揭示队列研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39902054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250205194943&amp;v=2.18.0.post9+e462414<description>结论：我们的研究确定了四个具有不同MPA结果的独特亚组。可能需要为每个亚组的个性化处理来改善MPA的预后。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025年1月20日； 15：1450153。 doi：10.3389/fimmu.2024.1450153。 eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：这项研究旨在使用基于主要成分分析（PCA）的群集分析来确定显微镜聚血管炎（MPA）的新临床表型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在2005年5月至2021年12月之间，共有189例MPA患者来自日本的多中心队列（揭示了队列）。基于临床，实验室和放射学发现进行了分类PCA和聚类分析。在每个群集之间比较了临床特征和结果，包括全因死亡率，与呼吸有关的死亡率，终点肾脏疾病（ESRD）和复发。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：使用分类PCA将11个临床变量转化为四个组件，并创建了合成变量。此外，使用这些变量进行了群集分析，以将MPA患者分类为亚组。确定了四个不同的临床亚组：群集1包括肾脏受累和弥漫性肺泡出血（DAH） - 主导组（n = 33）。群集2包括老年人的系统炎症组（n = 75）。群集3包括年轻的有限器官疾病组的患者（n = 45）。群集4由没有肾脏参与的ILD-PREDOMINALS组组成（n = 36）。在随访期间，有61例患者死亡，32例死亡呼吸有关的原因。此外，19例患者发育于ESRD，70例复发。群集1显示出最差的无ESRD生存率和复发率，而群集2显示了这四组中最差的总生存期和与呼吸有关的无死亡生存率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究确定了四个具有不同MPA结果的独特亚组。可能需要为每个亚组的个性化处理来改善MPA的预后。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39902054/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">39902054</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11788177/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250205194943&v=2.18.0.post9+e462414">PMC11788177</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1450153>10.3389/fimmu.2024.1450153</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39902054</guid><pubDate> Tue, 04 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Ayana Okazaki</dc:creator><dc:creator> Shogo Matsuda</dc:creator><dc:creator> Takuy​​a Kotani</dc:creator><dc:creator>福岛的keisuke</dc:creator><dc:creator> takaho gon</dc:creator><dc:creator> Ryu渡边</dc:creator><dc:creator>atsushi manabe</dc:creator><dc:creator> Mikihito Shoji</dc:creator><dc:creator> Keiichiro Kadoba</dc:creator><dc:creator> Ryosuke Hiwa</dc:creator><dc:creator> Yamamoto Wataru</dc:creator><dc:creator> Motomu Hashimoto</dc:creator><dc:creator> Tohru Takeuchi</dc:creator><dc:date> 2025-02-04</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title>使用聚类分析鉴定微观多管炎患者的新型临床亚型：多中心揭示队列研究</dc:title><dc:identifier>PMID：39902054</dc:identifier><dc:identifier> PMC：PMC11788177</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1450153</dc:identifier></item></channel></rss>